Personalized cancer care: genetic analysis may unlock targeted treatments for advanced lung cancer

NCT ID NCT02178163

Ongoing Knowledge-focused Sponsor: Barbara Ann Karmanos Cancer Institute Source: ClinicalTrials.gov ↗

First seen Jul 29, 2026 · Last updated Jul 30, 2026 · Updated 1 time

Summary

This trial investigates whether comprehensive genomic analysis of tumor tissue can help doctors choose targeted therapies for patients with advanced non-small cell lung cancer. Participants provide tumor samples (from past biopsies or new ones) for genetic testing. The goal is to see if this approach increases the number of patients who receive mutation-matched treatments.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: comprehensive genomic analysis of tumor specimens
What this could lead to: If successful, this approach could help doctors select more effective, personalized treatments for advanced lung cancer based on each tumor's genetic profile.
What could go wrong: This is an early-stage observational study, not a treatment trial. It may not show that genomic-guided therapy improves outcomes, and some patients may not have actionable mutations.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RECURRENT NON-SMALL CELL LUNG CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

RECURRENT NON-SMALL CELL LUNG CANCER STAGE IV NON-SMALL CELL LUNG CANCER

Contacts and locations

Locations

Barbara Ann Karmanos Cancer Institute

Detroit, Michigan, 48201, United States
KCI At McLaren Clarkston

Clarkston, Michigan, 48346, United States
KCI at McLaren Bay Region

Bay City, Michigan, 48708, United States
KCI at McLaren Central Michigan

Mount Pleasant, Michigan, 48858, United States
KCI at McLaren Flint

Flint, Michigan, 48532, United States
KCI at McLaren Greater Lansing, Mid Michigan Physicians

Lansing, Michigan, 48910, United States
KCI at McLaren Lapeer Region

Lapeer, Michigan, 48446, United States
KCI at McLaren Macomb

Mount Clemens, Michigan, 48043, United States
KCI at McLaren Port Huron

Port Huron, Michigan, 48060, United States
KCI at Mclaren Bloomfield Hills

Bloomfield Hills, Michigan, 48302, United States
KCI at Northern Michigan

Petoskey, Michigan, 49770, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.